The neurogenic vasoconstrictor effect of digitalis on coronary vascular resistance.
The coronary vasoconstrictor properties of digitals were evaluated in 61 anesthetized, openchest dogs after coronary sinus cannulation and under conditions of a constant heart rate (atrioventricular pacing) and near-constant blood pressure. The contribution of alpha adrenergic receptor stimulation to the digitalis-induced increase in coronary vascular resistance (CVR) was examined. With Na pentobarbital anesthesia (16 dogs), intravenous acetylstrophanthidin (0.5 mg) caused a significant (P<0.05) rise in CVR from 1 through 9 min after injection. The peak increase was +11+/-2% SE of the control of 1.8+/-0.2 mm Hg/cm(3)/min. The mean time to peak effect was 3 min, and to recovery was 21 min. Prior alpha adrenergic receptor blockade with phenoxybenzamine in 11 animals reduced (P<0.05) the acetylstrophanthidin-induced peak of CVR and substantially decreased (P<0.05) the time to recovery (5 min). Intravenous digoxin (1.0 mg) with Na pentobarbital anesthesia (five dogs) had no significant effect on CVR. However, with chloralose and urethane anesthesia (nine dogs) the same dose of digoxin produced a significant rise in CVR from 3 through 30 min. The peak increase was +20+/-3% of control (1.4+/-0.1 mm Hg/cm(3)/min). One-third the dose of intravenous digoxin (0.35 mg) produced a 9.5+/-1.0% increase in CVR (five additional dogs). Myocardial oxygen consumption did not change significantly in nine dogs after intravenous digoxin. In 10 additional dogs pretreated with phenoxy-benzamine and in 7 dogs pretreated with mecamylamine, the increase in CVR did not occur after 1.0 mg of intravenous digoxin. Thus there is a coronary vasoconstrictor effect of intravenous acetylstrophanthidin and digoxin, of rapid onset, which is mediated through alpha adrenergic receptor stimulation.
D001794:Blood Pressure / Q000187:drug effects; D002698:Chloralose / Q000494:pharmacology; D003331:Coronary Vessels / Q000187:drug effects*; D004071:Digitalis Glycosides / Q000378:metabolism / Q000494:pharmacology*; D004077:Digoxin / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D008464:Mecamylamine / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D010643:Phenoxybenzamine / Q000494:pharmacology; D013997:Time Factors; D014520:Urethane / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects
D004071:Digitalis Glycosides; D010643:Phenoxybenzamine; D002698:Chloralose; D014520:Urethane; D008464:Mecamylamine; D004077:Digoxin